“Both VX-150 and VX-128 represent an innovative new approach to the treatment of pain, and we are encouraged to now have positive proof-of-concept data from two studies of VX-150 that demonstrate for ...

Vertex Pharmaceuticals Incorporated VRTX announced positive results from a phase II study evaluating its NaV1.8 inhibitor VX-150 in patients suffering from pain caused by small fiber neuropathy. The ...

Vertex Pharmaceuticals today announced positive results of a Phase 2 study of the NaV1.8 inhibitor VX-150 in patients with acute pain following bunionectomy surgery. -VX-150 was generally well ...

-Treatment with the NaV1.8 inhibitor VX-150 showed significant relief of pain in patients with small fiber neuropathy and was generally well tolerated- -Third positive Phase 2 proof-of-concept study ...

Vertex has stopped development of VX-961 after getting a look at phase 1 data. The NaV1.8 inhibitor failed to meet Vertex’s desired pharmacokinetic and tolerability profile, leading it to dump the ...

Treatment with the NaV1.8 inhibitor VX-150 showed significant relief of pain in patients with small fiber neuropathy and was generally well tolerated. -Treatment with the NaV1.8 inhibitor VX-150 ...

A candidate has emerged as a front-runner in Vertex’s quest for the perfect non-opioid pain drug. The Boston-based biotech says its selective NaV1.8 inhibitor VX-548 will now push on to a midstage ...

BOSTON, August 04, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, ...

Vertex's VX-548 shows promising efficacy and safety in neuropathic pain management, potentially outperforming Lyrica. Q3 financials are strong: 6% revenue growth, 87.16% gross profit margin, driven by ...